Human medicines European public assessment report (EPAR): Lumark, lutetium, isotope of mass 177, Radionuclide Imaging, Date of authorisation: 18/06/2015, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Striascan, ioflupane (123i), Radionuclide Imaging,Dementia,Movement Disorders, Date of authorisation: 25/06/2019

Case Medical Research ◽

10.31525/cmr-193042a ◽

2019 ◽

Author(s):

Keyword(s):

Radionuclide Imaging ◽

Movement Disorders ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): EndolucinBeta, lutetium (177 Lu) chloride, Radionuclide Imaging, Date of authorisation: 06/07/2016, Revision: 5, Status: Authorised

Case Medical Research ◽

10.31525/cmr-838f1a ◽

2019 ◽

Author(s):

Keyword(s):

Radionuclide Imaging ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Axumin, fluciclovine (18F), Prostatic Neoplasms,Radionuclide Imaging, Date of authorisation: 21/05/2017, Revision: 6, Status: Authorised

Case Medical Research ◽

10.31525/cmr-56e4d8 ◽

2019 ◽

Author(s):

Keyword(s):

Prostatic Neoplasms ◽

Radionuclide Imaging ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Neuraceq, florbetaben (18F), Radionuclide Imaging,Alzheimer Disease, Date of authorisation: 20/02/2014, Revision: 14, Status: Authorised

Case Medical Research ◽

10.31525/cmr-b07ad1 ◽

2019 ◽

Author(s):

Keyword(s):

Alzheimer Disease ◽

Radionuclide Imaging ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): SomaKit TOC, edotreotide, Neuroendocrine Tumors,Radionuclide Imaging, Date of authorisation: 08/12/2016, Revision: 3, Status: Authorised

Case Medical Research ◽

10.31525/cmr-b9c421 ◽

2019 ◽

Author(s):

Keyword(s):

Neuroendocrine Tumors ◽

Radionuclide Imaging ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Axumin, fluciclovine (18F), Prostatic Neoplasms,Radionuclide Imaging, Date of authorisation: 21/05/2017, Revision: 6, Status: Authorised

Case Medical Research ◽

10.31525/cmr-5871d8 ◽

2019 ◽

Author(s):

Keyword(s):

Prostatic Neoplasms ◽

Radionuclide Imaging ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Vizamyl, flutemetamol (18F), Radionuclide Imaging,Alzheimer Disease, Date of authorisation: 22/08/2014, Revision: 9, Status: Authorised

Case Medical Research ◽

10.31525/cmr-1891661 ◽

2019 ◽

Author(s):

Keyword(s):

Alzheimer Disease ◽

Radionuclide Imaging ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Lymphoseek, tilmanocept, Radionuclide Imaging, Date of authorisation: 19/11/2014, Revision: 5, Status: Authorised

Case Medical Research ◽

10.31525/cmr-1db7e8c ◽

2019 ◽

Author(s):

Keyword(s):

Radionuclide Imaging ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Lumark, lutetium (177 Lu) chloride, Radionuclide Imaging, Date of authorisation: 18/06/2015, Revision: 7, Status: Authorised

Case Medical Research ◽

10.31525/cmr-8b84c4 ◽

2019 ◽

Author(s):

Keyword(s):

Radionuclide Imaging ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): SomaKit TOC, edotreotide, Neuroendocrine Tumors,Radionuclide Imaging, Date of authorisation: 08/12/2016, Revision: 3, Status: Authorised

Case Medical Research ◽

10.31525/cmr-b969bd ◽

2019 ◽

Author(s):

Keyword(s):

Neuroendocrine Tumors ◽

Radionuclide Imaging ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text